|
EP0859841B1
(en)
*
|
1995-08-18 |
2002-06-19 |
MorphoSys AG |
Protein/(poly)peptide libraries
|
|
US6037454A
(en)
|
1996-11-27 |
2000-03-14 |
Genentech, Inc. |
Humanized anti-CD11a antibodies
|
|
AU1728800A
(en)
|
1998-11-18 |
2000-06-05 |
Genentech Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
|
JP4334866B2
(ja)
|
2000-10-09 |
2009-09-30 |
アイシス イノヴェイション リミテッド |
治療用抗体
|
|
US7465790B2
(en)
|
2000-10-09 |
2008-12-16 |
Isis Innovation, Inc. |
Therapeutic antibodies
|
|
US20040109855A1
(en)
*
|
2002-07-23 |
2004-06-10 |
Herman Waldmann |
Therapeutic antibodies with reduced side effect
|
|
KR20060002896A
(ko)
*
|
2003-03-31 |
2006-01-09 |
기린 비루 가부시키가이샤 |
항 ｃｄ52 항체에 의한 조절성 ｔ 세포 분화 유도ㆍ증식방법 및 그를 위한 의약 조성물
|
|
NZ550815A
(en)
*
|
2004-05-19 |
2009-04-30 |
Immunocore Ltd |
Method of improving T cell receptors
|
|
AU2006226192A1
(en)
*
|
2005-03-19 |
2006-09-28 |
Medical Research Council |
Improvements in or relating to treatment and prevention of viral infections
|
|
PE20070207A1
(es)
*
|
2005-07-22 |
2007-03-09 |
Genentech Inc |
Tratamiento combinado de los tumores que expresan el her
|
|
US20100197896A1
(en)
*
|
2007-05-16 |
2010-08-05 |
Leung Shui-On |
Functional humanization of complementarity determining regions (cdrs)
|
|
EP2190861A4
(en)
|
2007-08-22 |
2011-03-30 |
Univ California |
ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
US8399219B2
(en)
|
2009-02-23 |
2013-03-19 |
Cytomx Therapeutics, Inc. |
Protease activatable interferon alpha proprotein
|
|
MX2011012047A
(es)
|
2009-05-13 |
2011-12-14 |
Genzyme Corp |
Inmunoglobulinas humanas anti-cd52.
|
|
NZ596603A
(en)
|
2009-05-29 |
2013-07-26 |
Morphosys Ag |
A collection of antibodies or fragments having properties relevant to developability
|
|
EP2640742B1
(en)
|
2010-11-19 |
2018-08-15 |
MorphoSys AG |
A collection of antibody sequences its use
|
|
GB201109238D0
(en)
*
|
2011-06-01 |
2011-07-13 |
Antitope Ltd |
Antibodies
|
|
US9494597B2
(en)
*
|
2012-04-02 |
2016-11-15 |
Ab Biosciences, Inc. |
Human control antibodies and uses therefor
|
|
PE20150605A1
(es)
|
2012-04-27 |
2015-05-28 |
Cytomx Therapeutics Inc |
Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
|
|
US20160030384A1
(en)
|
2013-04-09 |
2016-02-04 |
Boston Biomedical, Inc. |
2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
US20160120158A1
(en)
*
|
2014-11-03 |
2016-05-05 |
The Johns Hopkins University |
Compositions and methods for the study and treatment of acute kidney injury
|
|
WO2016196935A1
(en)
|
2015-06-03 |
2016-12-08 |
Boston Biomedical, Inc. |
Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
|
|
CA3045306A1
(en)
|
2016-11-29 |
2018-06-07 |
Boston Biomedical, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
JP2020520923A
(ja)
|
2017-05-17 |
2020-07-16 |
ボストン バイオメディカル， インコーポレイテッド |
がんを処置するための方法
|
|
EP3962926A4
(en)
|
2019-04-30 |
2022-11-23 |
Institute For Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center |
COMPOSITIONS AND METHODS FOR MODULATION OF ANTIBODY ACTIVITY
|